

**Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up**

<b>Rs. Mio.</b>	<b>Q4 16-17</b>	<b>Q4 15-16</b>	<b>% Gr y-y</b>	<b>YTD 16-17</b>	<b>YTD 15-16</b>	<b>% Gr y-y</b>
<b>Formulations Business - Key Markets</b>	<b>20,299</b>	<b>19,212</b>	<b>5.7%</b>	<b>77,024</b>	<b>76,934</b>	<b>0.1%</b>
US Formulations	9,851	9,610	2.5%	37,090	40,215	-7.8%
India Formulations	8,402	7,716	8.9%	32,441	29,852	8.7%
Latin America Formulations	603	553	9.0%	2,445	2,177	12.3%
Emerging Markets Formulations	1,444	1,333	8.4%	5,048	4,689	7.6%
<b>Other Businesses and Alliances</b>	<b>4,342</b>	<b>4,015</b>	<b>8.1%</b>	<b>17,133</b>	<b>15,685</b>	<b>9.2%</b>
Europe Formulations	620	705	-12.1%	2,623	2,950	-11.1%
Consumer Wellness	1,200	1,057	13.6%	4,593	4,242	8.3%
Animal Health & Others	1,074	844	27.3%	4,530	3,199	41.6%
APIs	934	922	1.3%	3,795	3,647	4.1%
Alliances	514	487	5.4%	1,591	1,647	-3.4%
<b>Grand Total</b>	<b>24,642</b>	<b>23,227</b>	<b>6.1%</b>	<b>94,156</b>	<b>92,618</b>	<b>1.7%</b>

**Cadila Healthcare Ltd.**

**Details of other incomes**

Rs. Mio.	Q4 16-17	Q4 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
<b>Other Operating Income</b>	<b>608</b>	<b>644</b>	<b>-5.6%</b>	<b>2,097</b>	<b>3,551</b>	<b>-40.9%</b>
Export Incentive	214	346	-38.1%	859	1,226	-29.9%
Royalty Income	2	10	-84.7%	68	179	-62.1%
Net Gain on foreign currency transactions and translation (Refer Note below)	-81	36	-324.7%	112	340	-67.1%
Others	474	251	88.3%	1,058	1,806	-41.4%

Note : There was a net loss of Rs. 264 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods in Q4 16-17. Thus, on aggregate level, there was a loss of Rs. 345 Mio. on operating transactions (above EBIDTA line) in Q4 16-17 vs gain of Rs. 14 Mio. in Q4 15-16. See details below for more clarity.

Rs. Mio.	Q4 16-17	Q4 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
<b>Other Income</b>	<b>731</b>	<b>395</b>	<b>85.1%</b>	<b>1,286</b>	<b>1,158</b>	<b>11.0%</b>
Interest & Dividend income	162	172	-5.6%	578	631	-8.5%
Profit on sale of investments	-11	-57	80.9%	61	140	-56.2%
Others	579	280	107.2%	646	386	67.4%

**Details of Foreign Exchange Fluctuations**

Rs. Mio. (+ = loss, - = gain)	Q4 16-17	Q4 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
<b>A. On operating transactions (above EBIDTA line)</b>	<b>345</b>	<b>-14</b>	<b>2556.6%</b>	<b>-62</b>	<b>-709</b>	<b>91.3%</b>
a. Included in other income	81	-36	324.7%	-112	-340	67.1%
b. Included in cost of goods	264	22	1100.0%	50	-369	113.6%
<b>B. On Foreign Currency Borrowings (part of interest cost)</b>	<b>-159</b>	<b>15</b>	<b>-1160.0%</b>	<b>-185</b>	<b>59</b>	<b>-413.6%</b>
<b>Total Foreign Currency Fluctuations (+ = loss, - = gain)</b>	<b>186</b>	<b>1</b>	<b>19355.9%</b>	<b>-247</b>	<b>-650</b>	<b>62.0%</b>

**Details of R&D Expenses**

Rs. Mio.	Q4 16-17	Q4 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
<b>Total R&amp;D Expenses</b>	<b>2,180</b>	<b>1,812</b>	<b>20.3%</b>	<b>7,539</b>	<b>7,594</b>	<b>-0.7%</b>

Consolidated Capex for Apr 16 - Mar 17

Rs. 29305  
Mio.

R&D capex included in above for Apr 16 - Mar 17

Rs. 331  
Mio.